{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 39,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 58,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/17",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.29,
        "w": 0.38,
        "x": 0.56,
        "y": 0.56
      },
      "kind": "list",
      "text": "None of the SAEs reported were deemed related to study drug\nNo evidence of cataract formation up to 12 weeks\nIntraocular pressure (IOP) increase consistent with literature\nMinimal mean IOP increase was similar across loading and maintenance phases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b95d7dc5-5853-482a-885f-a2f124ee86d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.51,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "TEAE, treatment-emergent adverse event.\nData, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7db0d931-a1f3-49e8-bb45-8ca8587c9dcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.69,
        "w": 0.51,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "table",
      "text": "Treatment Emergent Adverse Events\nOCS-01 (N = 100) n (%)\nVehicle (N = 48) n (%)\nAny TEAE 70 (70.0) 30 (62.5)\nDiabetic retinal edema 10 (10.0) 9 (18.8)\nIntraocular pressure increased 14 (14.0) 1 (2.1)\nHypertension 10 (10.0) 1 (2.1)\nOcular hypertension 8 (8.0) 0\nMacular edema 2 (2.0) 4 (8.3)\nCOVID-19 2 (2.0) 2 (4.2)\nDry eye 3 (3.0) 1 (2.1)\nDiabetes mellitus 3 (3.0) 0\nDizziness 3 (3.0) 0\nDysgeusia 3 (3.0) 0\nNasopharyngitis 2 (2.0) 1 (2.1)\nType 2 diabetes 2 (2.0) 1 (2.1)\nVisual acuity reduced 1 (1.0) 2 (4.2)\nVitreous haemorrhage 2 (2.0) 1 (2.1)\nArthralgia 2 (2.0) 0\nBlood glucose increased 2 (2.0) 0",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1526e44f-c777-41e3-9cb3-884bcb969403",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.33,
        "w": 0.38,
        "x": 0.55,
        "y": 0.16
      },
      "kind": "table",
      "text": "Treatment Emergent Serious Adverse Events (SAE)\nOCS-01 (N = 100) n (%)\nVehicle (N = 48) n (%)\nAny ocular SAE 1 (1.0) 0\nVitreous haemorrhage 1 (1.0) 0\nAny non-ocular SAE 4 (4.0) 3 (6.3)\nDeath 1 (1.0) 0",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ebfa985-e29e-4b3e-b83d-1006015565fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.56,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "No Unexpected Safety Findings",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efdd2871-df83-4b81-be39-11e2b59b2251",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 17,
      "beatId": "47165210-81f8-47ad-ae3f-2582e7380461",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 17-24 outline OCS-01's potential and the Phase 3 program.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}